MASLD, MetALD, and the Progression Spectrum to MASH & Cirrhosis
Understanding how metabolic risk factors and alcohol thresholds define MASLD vs. MetALD, drive cellular injury (MASH), and progress across fibrosis stages F1–F4.
Having fat in your liver (simple steatosis, or MASLD) is an early warning sign, not an automatic sentence to liver failure. The real turning point happens when excess fat — sometimes compounded by moderate alcohol intake in the newly recognized 'MetALD' overlap zone — triggers ongoing liver cell swelling (ballooning) and inflammation (MASH), laying down scar tissue graded from F0 to F4 (cirrhosis).
Because European and US guidelines list alcohol cutoffs in grams per day (20 g/day for women, 30 g/day for men) rather than American drink sizes, we built the private calculator below to convert your weekly pours into US standard drinks (14 g each) and explain the whole-blood PEth test doctors use when alcohol history is uncertain.
Disease Continuum: From Simple Steatosis to Cirrhosis
Metabolic dysfunction–associated steatotic liver disease
- Steatotic liver disease + presence of ≥1 cardiometabolic criterion, with exclusion of excessive alcohol intake and other causes of steatosis1
Metabolic dysfunction–associated steatohepatitis
Active form of the disease characterized by histologic features:
- Hepatocellular ballooning
- Lobular inflammation
Progressive Scar Accumulation
Stages of fibrosis:
- Mild: F1
- Moderate / Advanced (“At-Risk”): F2 / F3
Advanced Bridging Scarring & Remodeling
Stage F4 cirrhosis carries substantially elevated risk for portal hypertension, hepatic decompensation, and hepatocellular carcinoma.
Cardiometabolic Risk Factors1
- Overweight / obesity (BMI ≥25 kg/m², or ≥23 kg/m² in Asian adults) or elevated waist circumference
- Prediabetes or T2D
- Elevated triglycerides (≥150 mg/dL)
- Low HDL cholesterol
- Hypertension (≥130/85 mmHg)
SLD Alcohol Thresholds & US Drink Math1,4
1 US standard drink = 14 g pure alcohol (12 oz 5% beer, 5 oz 12% wine, or 1.5 oz 40% spirits):
- MASLD: <20 g/d (<140 g/wk; <10 drinks/wk) in women; <30 g/d (<210 g/wk; <15 drinks/wk) in men
- MetALD (Dual Metabolic + Alcohol): 20–50 g/d (10–25 drinks/wk) in women; 30–60 g/d (15–30 drinks/wk) in men
- ALD: >50 g/d women / >60 g/d men
Histology vs. Noninvasive Care2–4
Liver biopsy remains the microscopic reference standard to see hepatocyte ballooning, yet AASLD now endorses biopsy-free NIT staging (VCTE, MRE, ELF) to select non-cirrhotic F2–F3 MASH patients for approved therapies.2–4
Interactive US Standard Drink & MetALD Zone Calculator
100% Private • Runs in BrowserClinical guidelines define MASLD vs. MetALD in grams of pure ethanol per day or week, while US labels list fluid ounces and % ABV (1 US standard drink = 14 g pure alcohol). Enter a typical week below to translate pours into grams and guideline zones.
Objective Alcohol Biomarker: Whole-Blood Phosphatidylethanol (PEth)1,5
Because pour sizes vary widely and self-reported history misses moderate intake in 30%–40% of clinic visits, AASLD and EASL guidelines support whole-blood PEth (Labcorp 164840, Quest 36785, Mayo PETH) — a direct red-blood-cell membrane phospholipid metabolite measuring cumulative alcohol exposure over the prior 2–4 weeks:
| Whole-Blood PEth | Typical Intake Correlate | Steatotic Liver Disease (SLD) Interpretation |
|---|---|---|
| <20 ng/mL | Abstinence or light/minimal intake | Consistent with pure MASLD when cardiometabolic criteria are present1,5 |
| 20 – 199 ng/mL | Moderate regular alcohol intake | Supports MetALD classification; highlights dual metabolic + alcohol counseling opportunity1,5 |
| ≥200 ng/mL | Chronic heavy alcohol consumption | Consistent with ALD (or severe alcohol-predominant MetALD)1,5 |